Aafeen Mujeeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aafeen Mujeeb has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Gurakar
Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication - Ali Emre Bardak
Department of Medicine, Boston Medical Center-Brighton, Boston, MA 02135, USA
1 shared publication - Ayse Eylul Donmez
Children's Hospital, University of Illinois, Chicago, USA
1 shared publication - Behnam Saberi
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
1 shared publication - Eda Yildiz
Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, USA
1 shared publication - Hakim Ullah Wazir
Department of Medicine Medical Teaching Institute—Lady Reading Hospital Peshawar Pakistan
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Wiley in Public Health Challenges
- Vol. 5 (4)
Persistent Immune Thrombocytopenia as a Post‐Acute Sequelae of COVID‐19: A Case Report
Immune thrombocytopenia (ITP) is a recognized hematologic complication associated with coronavirus disease 2019 (COVID‐19), but its persistence years after acute infection remains uncommon. We present a case of a 52‐year‐old male who was diagnosed with COVID‐19 in June 2020. Following recovery from the acute illness, he had persistent fatigue, reduced energy levels, and poor appetite. Laboratory testing at his first follow‐up revealed thrombocytopenia with a platelet count of 60,000/mm 3 . He had no bleeding manifestations or organomegaly. A trial of oral corticosteroids in a tapering dose produced a partial response, with the platelet count rising to 94,000/mm 3 . Subsequently, a bone marrow biopsy was performed, confirming the diagnosis of ITP, excluding infiltration and dysplasia. Over the following 5 years, the patient continued to demonstrate persistent thrombocytopenia requiring a close clinical monitoring and follow‐up. This case highlights persistent ITP as a long‐term sequela of COVID‐19, extending more than 4 years after the initial infection. It underscores the importance of considering post‐COVID hematologic complications in patients presenting with chronic thrombocytopenia and emphasizes the need for ongoing surveillance and individualized management strategies.
- 6 October 2026
- Published by Wiley in Public Health Challenges
- Vol. 5 (4)
Open AccessPersistent Immune Thrombocytopenia as a Post‐Acute Sequelae of COVID‐19: A Case Report
Immune thrombocytopenia (ITP) is a recognized hematologic complication associated with coronavirus disease 2019 (COVID‐19), but its persistence years after acute infection remains uncommon. We present a case of a 52‐year‐old male who was diagnosed with COVID‐19 in June 2020. Following recovery from the acute illness, he had persistent fatigue, reduced energy levels, and poor appetite. Laboratory testing at his first follow‐up revealed thrombocytopenia with a platelet count of 60,000/mm 3 . He had no bleeding manifestations or organomegaly. A trial of oral corticosteroids in a tapering dose produced a partial response, with the platelet count rising to 94,000/mm 3 . Subsequently, a bone marrow biopsy was performed, confirming the diagnosis of ITP, excluding infiltration and dysplasia. Over the following 5 years, the patient continued to demonstrate persistent thrombocytopenia requiring a close clinical monitoring and follow‐up. This case highlights persistent ITP as a long‐term sequela of COVID‐19, extending more than 4 years after the initial infection. It underscores the importance of considering post‐COVID hematologic complications in patients presenting with chronic thrombocytopenia and emphasizes the need for ongoing surveillance and individualized management strategies.
- Open Access
- 13 May 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Using Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients
Liver transplantation (LT) remains the only definitive treatment for end-stage liver disease and selected hepatic malignancies. However, persistent organ shortages continue to drive high waitlist mortality worldwide. Hepatitis B virus (HBV)-positive donors, including hepatitis B surface antigen (HBsAg)-positive and anti-hepatitis B core antibody–positive (HBsAg negative) donors, represent an increasingly important but historically underused resource. The introduction of high-barrier nucleos(t)ide analogs, the selective use of hepatitis B immunoglobulin, and pre- and posttransplant vaccination have markedly reduced viral transmission, enabling safe transplantation in both HBV-immune and selected HBV-naive recipients. Regional guidelines and consensus statements, including those from the American Society of Transplantation, European Association for the Study of the Liver, American Association for the Study of Liver Diseases, and Asian Pacific Association for the Study of the Liver, support individualized, risk-directed prophylaxis and posttransplant surveillance. Ethical considerations, particularly informed consent and risk–benefit discussions in the setting of organ scarcity, remain central to clinical decision-making. Large cohort studies demonstrate comparable graft and patient survival with HBV-negative grafts, along with economic advantages and expansion of the donor pool. However, evidence in HBV-naive recipients remains limited, with most data derived from immune or previously infected recipients, highlighting the need for careful patient selection and robust prophylaxis. Available evidence on the use of HBsAg-positive donors in HBV-naive recipients is obtained predominantly from cadaveric donor transplantation, as experience with HBsAg-positive living donors remains limited. This narrative review summarizes current evidence on the use of HBsAg-positive grafts in LT, with a focus on HBV-naive recipients, based predominantly on cadaveric donor experience. Cite this article as: Bardak AE, Mujeeb A, Donmez AE, et al. Using hepatitis B surface antigen–positive donors in liver transplantation: Outcomes, prophylaxis, and monitoring with a focus on hepatitis B virus–naive recipients. Turk J Gastroenterol. Published online May 13, 2026. doi: 10.5152/tjg.2026.26018.
- 13 May 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Open AccessUsing Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients
Liver transplantation (LT) remains the only definitive treatment for end-stage liver disease and selected hepatic malignancies. However, persistent organ shortages continue to drive high waitlist mortality worldwide. Hepatitis B virus (HBV)-positive donors, including hepatitis B surface antigen (HBsAg)-positive and anti-hepatitis B core antibody–positive (HBsAg negative) donors, represent an increasingly important but historically underused resource. The introduction of high-barrier nucleos(t)ide analogs, the selective use of hepatitis B immunoglobulin, and pre- and posttransplant vaccination have markedly reduced viral transmission, enabling safe transplantation in both HBV-immune and selected HBV-naive recipients. Regional guidelines and consensus statements, including those from the American Society of Transplantation, European Association for the Study of the Liver, American Association for the Study of Liver Diseases, and Asian Pacific Association for the Study of the Liver, support individualized, risk-directed prophylaxis and posttransplant surveillance. Ethical considerations, particularly informed consent and risk–benefit discussions in the setting of organ scarcity, remain central to clinical decision-making. Large cohort studies demonstrate comparable graft and patient survival with HBV-negative grafts, along with economic advantages and expansion of the donor pool. However, evidence in HBV-naive recipients remains limited, with most data derived from immune or previously infected recipients, highlighting the need for careful patient selection and robust prophylaxis. Available evidence on the use of HBsAg-positive donors in HBV-naive recipients is obtained predominantly from cadaveric donor transplantation, as experience with HBsAg-positive living donors remains limited. This narrative review summarizes current evidence on the use of HBsAg-positive grafts in LT, with a focus on HBV-naive recipients, based predominantly on cadaveric donor experience. Cite this article as: Bardak AE, Mujeeb A, Donmez AE, et al. Using hepatitis B surface antigen–positive donors in liver transplantation: Outcomes, prophylaxis, and monitoring with a focus on hepatitis B virus–naive recipients. Turk J Gastroenterol. Published online May 13, 2026. doi: 10.5152/tjg.2026.26018.